As of 09:44 on March 19, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 0.01%, the constituent stocks Jinxin Fertility (01951) rose 8.23%, Hansoh Pharmaceutical (03692) rose 4.80%, MicroPort (00853) rose 4.40%, Gushengtang (02273) rose 4.18%, and Hygeia Medical (06078) rose 3.97%. Hong Kong stock pharmaceutical ETF (159718) rose 0.42%, the latest price was 0.72 yuan, and the intraday turnover has reached 7.4434 million yuan, with a turnover rate of 3.32%.

As of 09:43 on March 19, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 0.05%, the constituent stocks Xingqi Eye Medicine (300573) rose 3.32%, Kelun Pharmaceutical (002422) rose 1.60%, Tebao Biotechnology (688278) rose 1.08%, Huitai Medical (688617) rose 0.92%, and Allist (688578) rose 0.86%. Medical Innovation ETF (516820) fell 0.28%, with the latest price of 0.35 yuan, and the intraday turnover has reached 7.9098 million yuan.

In the long run, as of March 18, 2025, Hong Kong stock pharmaceutical ETFs have risen by 6.09% in the past week, ranking 1/4 of comparable funds. Healthcare Innovation ETF has risen 2.92% over the past 1 week.

In terms of scale, the latest scale of medical innovation ETF reached 1.798 billion yuan. In terms of fund inflow, medical innovation ETFs have attracted a total of 15.5043 million yuan in the past 20 trading days.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 7.5819 million yuan, and the latest financing balance reached 83.4537 million yuan.

Hong Kong pharmaceutical stocks have risen sharply recently, and AI technology to improve R&D efficiency and favorable policies are the core drivers. China Merchants Securities believes that in 2025, policies such as medical insurance to support the high-quality development of innovative drugs and improve the drug price formation mechanism are expected to form a relay with the "whole chain support".

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.